Yahoo
OTC Markets OTCQX - Delayed Quote USD

Onward Medical N.V. (ONWRF)

2.3100 0.0000 (0.00%)
At close: October 30 at 5:00:00 PM EDT
ONWRF Q3 2026 earnings call
Today at 8 AM EST
Chart Range Bar
Loading chart for ONWRF
  • Previous Close 2.3100
  • Open 2.7100
  • Bid 2.3300 x 10000
  • Ask 2.4400 x 10000
  • Day's Range 2.7100 - 2.7100
  • 52 Week Range 2.3100 - 5.7000
  • Volume 400
  • Avg. Volume 97
  • Market Cap (intraday) 160.611M
  • Beta (5Y Monthly) 0.71
  • PE Ratio (TTM) --
  • EPS (TTM) -0.9900
  • Earnings Date Sep 9, 2026
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Onward Medical N.V., a medical technology company, develops and commercializes therapies to enable functional recovery for people with spinal cord injury (SCI) in the United States, Europe, and internationally. The company offers ARCEX System, an external stimulator that is intended to improve hand strength and sensation following SCI; ARCIM System, an implantable system currently used to explore potential indications in clinical feasibility studies; ARCBCI System, an implantable system currently being investigated to enable thought driven movement of the legs and upper extremities. Onward Medical N.V. was founded in 2014 and is headquartered in Eindhoven, Netherlands.

www.onwd.com

137

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is BEL 20 (^BFX) .

YTD Return

ONWRF
59.47%
BEL 20 (^BFX)
15.74%

1-Year Return

ONWRF
48.09%
BEL 20 (^BFX)
19.88%

3-Year Return

ONWRF
49.34%
BEL 20 (^BFX)
74.02%

5-Year Return

ONWRF
63.62%
BEL 20 (^BFX)
36.47%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -35.30%

  • Return on Equity (ttm)

    -90.85%

  • Revenue (ttm)

    8.42M

  • Net Income Avi to Common (ttm)

    -45.27M

  • Diluted EPS (ttm)

    -0.9900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    81.5M

  • Total Debt/Equity (mrq)

    19.17%

  • Levered Free Cash Flow (ttm)

    -29.07M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: